Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 12/20 | 0.49 |
| ▸ | SHBG | P04278 | 2/20 | 0.44 |
| ▸ | PGR | P06401 | 3/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14342102 | 1.00 | AR (0.50) | ARCYP19A1SHBGPGRNR3C2 | |
| SCHEMBL6376819 | 0.89 | CYP19A1 (0.52) | ARCYP19A1SHBGPGRNR3C2 | |
| SCHEMBL4588011 | 0.86 | CYP19A1 (0.49) | ARCYP19A1SHBGPGRNR3C2 | |
| SCHEMBL1897274 | 0.86 | CYP19A1 (0.49) | ARCYP19A1SHBGPGRNR3C2 | |
| SCHEMBL4588578 | 0.86 | CYP19A1 (0.49) | ARCYP19A1SHBGPGRNR3C2 | |
| SCHEMBL13804516 | 0.86 | CYP19A1 (0.49) | ARCYP19A1SHBGPGRNR3C2 | |
| SCHEMBL10947171 | 0.84 | CYP19A1 (0.47) | ARCYP19A1SHBGPGRNR3C2 | |
| SCHEMBL10943281 | 0.83 | CYP19A1 (0.46) | ARCYP19A1SHBGPGRNR3C2 | |
| SCHEMBL4587874 | 0.82 | CYP19A1 (0.47) | ARCYP19A1PGRNR3C2 | |
| SCHEMBL12902155 | 0.82 | CYP19A1 (0.64) | CYP19A1SHBGPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361645-B2 | Androgenic 7-substituted 11-halogen steroids | BAYER SCHERING PHARMA AG (DE) | 2008-04-22 | — | — | US | disclosed |
| EP-1353938-B1 | ANDROGENIC 7-SUBSTITUTED 11-HALOGENATED STEROIDS | BAYER SCHERING PHARMA AG (DE) | 2008-02-13 | — | — | EP | disclosed |
| US-20070298456-A1 | Microbiological process for the production of 7-substitued 11-hydroxy steroids, 7,17-substituted 11-halogen steroids, and uses thereof | ZORN LUDWIG | 2007-12-27 | — | — | US | disclosed |
| US-7262023-B2 | Microbiological process for the production of 7-substituted 11-hydroxy steroids, 7,17-substituted 11-Halogen steroids and uses thereof | BAYER SCHERING PHARMA AG (DE) | 2007-08-28 | — | — | US | disclosed |
| US-20050090477-A1 | Microbiological process for the production of 7-substituted 11-hydroxy steroids, 7,17-substituted 11-halogen steroids that can be produced therefrom, their process for production and use as well as pharmaceutical prepartions that contain these compounds, as well as 7-substituted estra-1,3,5(10)-trienses that can be produced therefrom | SCHERING AG (DE) | 2005-04-28 | — | — | US | disclosed |
| EP-1523568-A2 | MICROBIOLOGICAL METHOD FOR THE PRODUCTION OF 7 ALPHA-SUBSTITUTED 11 ALPHA-HYDROXYSTEROIDS | Schering Aktiengesellschaft (DE) | 2005-04-20 | — | — | EP | disclosed |
| US-20050075322-A1 | Androgenic 7-substituted 11-halogen steroids | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-04-07 | — | — | US | disclosed |
| WO-2004011663-A9 | MICROBIOLOGICAL METHOD FOR THE PRODUCTION OF 7 ALPHA-SUBSTITUTED 11 ALPHA-HYDROXYSTEROIDS | SCHERING AG (DE) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004011663-A2 | MICROBIOLOGICAL METHOD FOR THE PRODUCTION OF 7 ALPHA-SUBSTITUTED 11 ALPHA-HYDROXYSTEROIDS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-02-05 | — | — | WO | disclosed |
| US-6258803-B1 | 11-ETHYL-17-HYDROXY-19-NORPREGN-4-EN-20-YN-3-ONE FOR MENOPAUSE TREATMENT | AKZO NOBEL N.V. (NL) | 2001-07-10 | — | — | US | disclosed |
| US-6037339-A | METHOD FOR TREATING OSTEOPOROSIS | AKZO NOBEL N.V. (NL) | 2000-03-14 | — | — | US | disclosed |
| US-5710144-A | OSTEOPOROSIS | AKZO NOBEL N.V. (NL) | 1998-01-20 | — | — | US | disclosed |
| EP-0145493-B1 | 11-DIFLUOROMETHYL AND 11-FLUOROMETHYLENE STEROIDS | THE UPJOHN COMPANY (US) | 1989-03-08 | — | — | EP | disclosed |
| US-4557867-A | CONTRACEPTIVES | THE UPJOHN COMPANY (US) | 1985-12-10 | — | — | US | disclosed |
| EP-0145493-A2 | 11-Difluoromethyl and 11-fluoromethylene steroids | THE UPJOHN COMPANY (US) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075322-A1 | Androgenic 7-substituted 11-halogen steroids | NR5A1, HSD17B11, HSD11B1 | AR 16/4885CYP19A1 14/4885SHBG 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.